Form 4: Aldeyra Therapeutics Director Richard Douglas Receives Significant Stock Option Grant

Aldeyra Therapeutics, Inc. Director Richard Douglas was granted 78,893 stock options with an exercise price of $2.685, vesting over one year, as compensation for his board service.

Summary

• Richard Douglas, a Director at Aldeyra Therapeutics, Inc. (ALDX), acquired 78,893 stock options on June 10, 2025.
• The options have an exercise price of $2.685 per share.
• The total grant comprises three tranches: 62,728 options for general board service, 14,476 options for service as Chairperson of the Board, and 1,689 options for service on the Nominating/Corporate Governance Committee.
• All options become 100% exercisable on the one-year anniversary of the grant date (June 10, 2026), contingent upon continuous service in the respective roles.
• The options have an expiration date of June 9, 2035.
• The derivative securities were acquired at a price of $0, indicating they were granted as compensation.

Sentiment

Score: 7

Explanation: The document reports a routine equity compensation grant to a director, which is a positive for aligning management interests with shareholders but does not indicate significant new operational or financial performance. It's a standard governance disclosure.

Positives

• The grant of stock options aligns the financial interests of Director Richard Douglas with those of Aldeyra Therapeutics shareholders, incentivizing long-term value creation.
• Equity compensation is a standard practice for retaining and motivating experienced board members.

Risks

• The exercisability of the stock options is contingent upon the Reporting Person providing continuous service as a member of the Board of Directors, Chairperson of the Board, and/or member of the Nominating/Corporate Governance Committee through the applicable vesting date.

Future Outlook

The grant of stock options with a one-year vesting period implies an expectation of continued service from Director Richard Douglas, aligning his future contributions with the company's performance.

Industry Context

The granting of stock options to directors is a common form of non-cash compensation in the biotechnology and pharmaceutical industries, used to attract and retain experienced talent and align their interests with long-term shareholder value.

Comparison to Industry Standards

• Equity compensation, such as stock option grants, is a widely accepted practice for non-employee directors across publicly traded companies, including those in the biotech sector like Aldeyra Therapeutics.
• The vesting schedule, typically over one year for director grants, is standard, ensuring continued commitment.
• The exercise price being set at the market price on the grant date is also a common feature of such compensatory grants.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholder value creation, as the options gain value only if the stock price increases above the exercise price.
• Employees: No direct impact mentioned, but it reinforces the company's compensation philosophy for key personnel.

Next Steps

• The stock options will become exercisable on June 10, 2026, provided Richard Douglas continues his service to the company's Board of Directors and its committees.

Key Dates

Recommendation

Keywords

Aldeyra Therapeutics, ALDX, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Corporate Governance, Biotechnology